EYPT - EyePoint Pharmaceuticals GAAP EPS of -$0.52 misses by $0.01 revenue of $11.6M beats by $0.74M
- EyePoint Pharmaceuticals press release ( NASDAQ: EYPT ): Q2 GAAP EPS of -$0.52 misses by $0.01 .
- Revenue of $11.6M (+28.7% Y/Y) beats by $0.74M .
- "We expect the cash, cash equivalents and investments on hand on June 30, 2022 and expected net cash inflows from our product sales will enable us to fund our current and planned operations into the second half of 2024."
For further details see:
EyePoint Pharmaceuticals GAAP EPS of -$0.52 misses by $0.01, revenue of $11.6M beats by $0.74M